HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)
South Korea · Delayed Price · Currency is KRW 2,880.00
-65.00 (-2.21%)
At close: Feb 6, 2026
HLB Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Other Revenue | -0 | - | -0 | -0 | - | - |
| 63,246 | 54,932 | 52,591 | 42,403 | 43,586 | 42,930 | |
Revenue Growth (YoY) | 16.82% | 4.45% | 24.03% | -2.72% | 1.53% | -27.20% |
Cost of Revenue | 56,015 | 44,953 | 45,406 | 33,682 | 38,579 | 36,464 |
Gross Profit | 7,231 | 9,979 | 7,184 | 8,721 | 5,007 | 6,466 |
Selling, General & Admin | 13,212 | 16,192 | 15,236 | 15,673 | 15,641 | 15,786 |
Amortization of Goodwill & Intangibles | 50.96 | 114.26 | 48.3 | 20.79 | 99.66 | 100.41 |
Other Operating Expenses | 248.21 | 301.46 | 183 | 273.11 | 240.04 | 218.66 |
Operating Expenses | 14,891 | 17,603 | 16,053 | 16,228 | 16,094 | 17,732 |
Operating Income | -7,660 | -7,624 | -8,869 | -7,507 | -11,087 | -11,267 |
Interest Expense | -2,027 | -1,964 | -1,112 | -5,146 | -1,160 | -4,254 |
Interest & Investment Income | 768.89 | 984.55 | 1,166 | 1,230 | 96.09 | 217.24 |
Earnings From Equity Investments | -6,569 | -3,153 | 802.4 | - | - | -909.06 |
Currency Exchange Gain (Loss) | 540.1 | 4,482 | 94.65 | 327.03 | 97.78 | -86.81 |
Other Non Operating Income (Expenses) | 201.31 | 1,363 | -3,430 | -1,334 | 15.88 | 5.87 |
EBT Excluding Unusual Items | -14,746 | -5,912 | -11,347 | -12,430 | -12,038 | -16,294 |
Gain (Loss) on Sale of Investments | 7,545 | -8,958 | 7,754 | 1,879 | -359.48 | 13.53 |
Gain (Loss) on Sale of Assets | 228.2 | -17.69 | 4.04 | -598.18 | -14.8 | 4.18 |
Asset Writedown | -2,242 | -8,037 | - | -424.08 | -4,632 | -1,953 |
Other Unusual Items | 1,074 | - | 624.11 | - | -720.83 | 829.12 |
Pretax Income | -8,140 | -22,926 | -2,965 | -11,573 | -17,764 | -17,401 |
Income Tax Expense | 263.25 | - | - | - | - | - |
Earnings From Continuing Operations | -8,404 | -22,926 | -2,965 | -11,573 | -17,764 | -17,401 |
Earnings From Discontinued Operations | 0 | -534.08 | -113.98 | -530.86 | - | - |
Net Income to Company | -8,404 | -23,460 | -3,079 | -12,104 | -17,764 | -17,401 |
Minority Interest in Earnings | 412.53 | 666.96 | 777.16 | 750.45 | 567.08 | 498.15 |
Net Income | -7,991 | -22,793 | -2,302 | -11,354 | -17,197 | -16,902 |
Net Income to Common | -7,991 | -22,793 | -2,302 | -11,354 | -17,197 | -16,902 |
Shares Outstanding (Basic) | 84 | 83 | 78 | 68 | 61 | 57 |
Shares Outstanding (Diluted) | 84 | 83 | 78 | 68 | 61 | 57 |
Shares Change (YoY) | 2.60% | 6.36% | 14.46% | 10.86% | 7.26% | 4.63% |
EPS (Basic) | -95.29 | -275.17 | -29.56 | -166.86 | -280.19 | -295.37 |
EPS (Diluted) | -95.29 | -275.17 | -29.56 | -166.86 | -280.19 | -295.37 |
Free Cash Flow | 4,823 | 650.79 | 3,025 | -12,204 | -12,091 | -11,736 |
Free Cash Flow Per Share | 57.51 | 7.86 | 38.84 | -179.37 | -196.99 | -205.09 |
Gross Margin | 11.43% | 18.17% | 13.66% | 20.57% | 11.49% | 15.06% |
Operating Margin | -12.11% | -13.88% | -16.86% | -17.70% | -25.44% | -26.24% |
Profit Margin | -12.63% | -41.49% | -4.38% | -26.78% | -39.45% | -39.37% |
Free Cash Flow Margin | 7.63% | 1.19% | 5.75% | -28.78% | -27.74% | -27.34% |
EBITDA | -1,679 | 467.85 | -389.34 | -5,841 | -9,386 | -10,566 |
EBITDA Margin | -2.66% | 0.85% | -0.74% | -13.78% | -21.54% | -24.61% |
D&A For EBITDA | 5,980 | 8,092 | 8,479 | 1,666 | 1,701 | 700.54 |
EBIT | -7,660 | -7,624 | -8,869 | -7,507 | -11,087 | -11,267 |
EBIT Margin | -12.11% | -13.88% | -16.86% | -17.70% | -25.44% | -26.24% |
Advertising Expenses | - | 0.69 | - | 0.21 | 7.07 | 32.42 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.